You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers at the University of Copenhagen used mass spectrometry to analyze dental plaque from 21 individuals recovered from a medieval Danish gravesite.
A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.
The American Dental Association wants insurers and test manufacturers to show genetic testing is scientifically valid before they're used to determine coverage eligibility.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
Geneticists and periodontists point to financial conflicts, the lack of genetics knowhow, and regulatory gaps for the availability of a test they say should have never come to market.
The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
The researchers found that patients with periodontitis exhibited patterns of autoantigen hypercitrullination similar to those found in RA patients.
Reanalysis of a prior study found no interaction between Interleukin's PST test and preventive visits or association with the patient outcome of tooth extraction.
Interleukin's revenues fell by more than 50 percent year over year due to a decrease in deferred revenue recognized, but it trimmed its Q4 net loss.
The company raised $5 million in private financing and is borrowing $5 million.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.